S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:EVOK

Evoke Pharma (EVOK) Stock Price, News & Analysis

$0.61
+0.02 (+3.39%)
(As of 03/28/2024 ET)
Today's Range
$0.59
$0.65
50-Day Range
$0.59
$0.79
52-Week Range
$0.56
$2.42
Volume
30,344 shs
Average Volume
63,715 shs
Market Capitalization
$5.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EVOK stock logo

About Evoke Pharma Stock (NASDAQ:EVOK)

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

EVOK Stock Price History

EVOK Stock News Headlines

Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
A Preview Of Evoke Pharma's Earnings
Evoke Pharma Inc Registered Shs hosts conference call for investors
Evoke Pharma Inc (EVOK)
EVOKE PHARMA INC.DL-,0001 (EV00.DU)
Evoke Pharma Inc
See More Headlines
Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EVOK
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-7,790,000.00
Net Margins
-150.43%
Pretax Margin
-150.40%

Debt

Sales & Book Value

Annual Sales
$5.18 million
Book Value
($0.77) per share

Miscellaneous

Free Float
7,479,000
Market Cap
$5.17 million
Optionable
Not Optionable
Beta
0.21
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. David A. Gonyer R.Ph. (Age 60)
    Co-Founder, CEO & Director
    Comp: $666.31k
  • Mr. Matthew J. D'Onofrio MBA (Age 54)
    Co-Founder, President, COO, Secretary & Treasurer
    Comp: $498.12k
  • Dr. Marilyn R. Carlson D.M.D. (Age 76)
    M.D., RAC., Chief Medical Officer
    Comp: $444.99k
  • Mr. Christopher Quesenberry
    Chief Commercial Officer - Gimoti (TM)

EVOK Stock Analysis - Frequently Asked Questions

How have EVOK shares performed in 2024?

Evoke Pharma's stock was trading at $1.0503 at the beginning of the year. Since then, EVOK stock has decreased by 41.9% and is now trading at $0.61.
View the best growth stocks for 2024 here
.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 72,100 shares, an increase of 21.8% from the February 29th total of 59,200 shares. Based on an average trading volume of 60,100 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.1% of the company's stock are sold short.
View Evoke Pharma's Short Interest
.

When is Evoke Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our EVOK earnings forecast
.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) issued its earnings results on Thursday, March, 14th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter. The specialty pharmaceutical company had revenue of $1.68 million for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative trailing twelve-month return on equity of 517.99%.

When did Evoke Pharma's stock split?

Evoke Pharma's stock reverse split on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What guidance has Evoke Pharma issued on next quarter's earnings?

Evoke Pharma updated its FY 2024 earnings guidance on Thursday, March, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.0 million-$14.0 million, compared to the consensus revenue estimate of $14.0 million.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVOK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners